Pre-surgical Evaluation of MK-2206 in Patients With Operable Invasive Breast Cancer

Trial Profile

Pre-surgical Evaluation of MK-2206 in Patients With Operable Invasive Breast Cancer

Discontinued
Phase of Trial: Phase II

Latest Information Update: 05 Jun 2018

At a glance

  • Drugs MK 2206 (Primary)
  • Indications Adenocarcinoma; Breast cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 05 Jun 2018 Results assessing the impact of Akt inhibition on the tumor microenvironment, presented at the 54th Annual Meeting of the American Society of Clinical Oncology
    • 09 Dec 2017 Results assessing tumor immune environment in Breast cancer patients presented at the 40th Annual San Antonio Breast Cancer Symposium.
    • 10 Jun 2017 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top